ClinicalTrials.gg
CompletedNCT00447005Updated May 23, 2012Results posted

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

A Phase 1 interventional study of Axitinib (AG-013736) in Carcinoma, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-05-23.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Carcinoma by Pfizer — 6 open to participants now, 6 under way, 2 of them phase 3. Carcinoma · Pfizer.

Enrollment
23rd of 24
12 · median 98
Started
2007
with 1 other
Phase 1
9 of 27
2 open now
Registered
8th of 27
by date

Among the 27 studies in Carcinoma by Pfizer, this one is the 23rd largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2007, is one of 9 in phase 1, and was the 8th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

6 of the 27 studies in Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma by Pfizer, or all of them as a file.
02

Study summary

To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.

03

Conditions studied

  • Carcinoma

Browse trials for

Keywords

  • Safety
  • PK
  • Biomarker
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients or cytologically diagnosed with advanced malignant solid tumors
  • Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies

Exclusion criteria

Exclusion Criteria:

  • Central lung lesions involving major blood vessels
  • Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Open

    Drug: Axitinib (AG-013736)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 3 or higher, serious adverse events, and adverse events resulted in discontinuation.

    Time frame: Up to 795 days of treatment plus 28-days follow-up

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax): Single Dose

    Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax): Single Dose

    Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose

  3. Area Under The Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf): Single Dose

    AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).

    Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose

  4. Terminal Phase Plasma Half-Life (t1/2): Single Dose

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose

  5. Maximum Observed Plasma Concentration (Cmax): Multiple Dose

    Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple Dose

    Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose

  7. Area Under The Plasma Concentration-Time Curve Over Dosing Interval Tau (AUCtau): Multiple Dose

    Dosing Interval was 12 hours in this study.

    Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose

  8. Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau): Multiple Dose

    Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)

    Time frame: Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose

  9. Percent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 2 and 3 (s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT)

    Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., VEGFR2, s-VEGFR3, s-KIT, and VEGF.

    Time frame: Prior to the initial dose (baseline), Day 1 of Cycle 2 and at the discontinuation

  10. The Numbers of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

    CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

    Time frame: Up to 795 days

07

Results

Posted Mar 26, 2012

Participant flow

Participant flow — Overall Study
MilestoneAG-013736
Started12
Completed0
Not completed12
Withdrew: Adverse event1
Withdrew: Lack of efficacy11

Outcome measures

PrimaryNumber of Participants With Adverse Events

Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 3 or higher, serious adverse events, and adverse events resulted in discontinuation.

Time frame:
Up to 795 days of treatment plus 28-days follow-up
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsAG-013736
Any adverse events12
Any serious adverse events5
Any Grade-3 or -4 adverse events7
Any Grade-5 adverse events (= death)0
Discontinuation due to adverse events1
SecondaryMaximum Observed Plasma Concentration (Cmax): Single Dose
Time frame:
Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Single Dose
ng/mLAG-013736
Maximum Observed Plasma Concentration (Cmax): Single Dose29.97 ± 9.97
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax): Single Dose
Time frame:
Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax): Single Dose
hoursAG-013736
Time to Reach Maximum Observed Plasma Concentration (Tmax): Single Dose4 (2 to 6)
SecondaryArea Under The Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf): Single Dose

AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).

Time frame:
Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under The Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf): Single Dose
ng*hr/mLAG-013736
Area Under The Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf): Single Dose210.3 ± 146.5
SecondaryTerminal Phase Plasma Half-Life (t1/2): Single Dose

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
Single dose: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, and 32 hours postdose
Reported as:
Mean · hours
Terminal Phase Plasma Half-Life (t1/2): Single Dose
hoursAG-013736
Terminal Phase Plasma Half-Life (t1/2): Single Dose4.8 ± 1.146
SecondaryMaximum Observed Plasma Concentration (Cmax): Multiple Dose
Time frame:
Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Multiple Dose
ng/mLAG-013736
Cycle 1 Day 1 (n=12)23.85 ± 10.94
Cycle 1 Day 15 (n=11)32.14 ± 18.04
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax): Multiple Dose
Time frame:
Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple Dose
hoursAG-013736
Cycle 1 Day 1 (n=12)3 (2 to 4)
Cycle 1 Day 15 (n=11)4 (1 to 4)
SecondaryArea Under The Plasma Concentration-Time Curve Over Dosing Interval Tau (AUCtau): Multiple Dose

Dosing Interval was 12 hours in this study.

Time frame:
Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Reported as:
Mean · ng*h/mL
Area Under The Plasma Concentration-Time Curve Over Dosing Interval Tau (AUCtau): Multiple Dose
ng*h/mLAG-013736
Cycle 1 Day 1 (n=12)137.3 ± 84.3
Cycle 1 Day 15 (n=11)187.8 ± 125.3
SecondaryAccumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau): Multiple Dose

Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)

Time frame:
Multiple dose Cycle 1 Day 1 and 15: predose, 0.5, 1, 2, 4, 8 and 12 hours postdose
Reported as:
Mean · ratio
Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau): Multiple Dose
ratioAG-013736
Rac Cmax (n=11)1.449 ± 0.471
Rac AUCtau (n=11)1.541 ± 0.489
SecondaryPercent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 2 and 3 (s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT)

Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., VEGFR2, s-VEGFR3, s-KIT, and VEGF.

Time frame:
Prior to the initial dose (baseline), Day 1 of Cycle 2 and at the discontinuation
Reported as:
Median · percent change
Percent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 2 and 3 (s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT)
percent changeAG-013736
s-VEGFR2: Cycle 2 Day 1 (n=12)-41.73 (-53.2 to -10.1)
s-VEGFR2: At discontinuation (n=11)-40.57 (-53.0 to -8.4)
s-VEGFR3: Cycle 2 Day 1 (n=12)-52.50 (-93.7 to -15.6)
s-VEGFR3: At discontinuation (n=11)-65.48 (-81.2 to 39.4)
s-KIT: Cycle 2 Day 1 (n=12)-0.26 (-23.8 to 33.5)
s-KIT: At discontinuation (n=11)4.66 (-31.2 to 12.9)
VEGF: Cycle 2 Day 1 (n=12)266.92 (14.9 to 1030.4)
VEGF: At discontinuation (n=11)43.48 (-15.5 to 423.1)
SecondaryThe Numbers of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

Time frame:
Up to 795 days
Reported as:
Number · participants
The Numbers of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
participantsAG-013736
CR0
PR0
SD10
PD2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG-013736—5/12 (41.7%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventAG-013736
Intestinal obstructionGastrointestinal disorders2/12
PyrexiaGeneral disorders2/12
Cardiac tamponadeCardiac disorders1/12
Liver abscessInfections and infestations1/12
Most frequent other events
Showing 10 of 72
Most frequent other events
EventAG-013736
Decreased appetiteMetabolism and nutrition disorders11/12
DiarrhoeaGastrointestinal disorders10/12
FatigueGeneral disorders10/12
StomatitisGastrointestinal disorders9/12
Blood thyroid stimulating hormone increasedInvestigations9/12
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders8/12
Blood urine presentInvestigations7/12
DysphoniaRespiratory, thoracic and mediastinal disorders7/12
ConstipationGastrointestinal disorders6/12
Aspartate aminotransferase increasedInvestigations6/12

Baseline characteristics

Age Continuous
Age Continuous(years)AG-013736
Mean60.2 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)AG-013736
Female5
Male7
08

Study locations

1 site
  • Pfizer Investigational Site
    Kashiwa, Chiba, Japan
09

References and documents

Publications

  • Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010 Apr;101(4):963-8. doi: 10.1111/j.1349-7006.2009.01465.x. Epub 2009 Dec 9. PubMed 20180805 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2007
First posted
Mar 13, 2007
Start
Feb 2007
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Mar 26, 2012
Last update
May 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00447005
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 13, 2007
Start date
Feb 2007
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Mar 26, 2012
Last update
May 23, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion